EU nod for Samsung Bioepis’ Remicade biosimilar
Samsung Bioepis’ biosimilar of Johnson & Johnson’s blockbuster anti-inflammatory infliximab has won regulatory approval in Europe, potentially further expanding access to anti-TNF therapies in the region.
Read More
